These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 12875709)

  • 41. Weight-based dosing of pegylated interferon-alpha in chronic hepatitis C: just a marketing 'gag'?
    Ferenci P
    Dig Liver Dis; 2003 Sep; 35(9):601-6. PubMed ID: 14563179
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pegylated interferon vs standard interferon for chronic hepatitis C.
    Menkes DL
    JAMA; 2005 Mar; 293(11):1323; author reply 1323-4. PubMed ID: 15769962
    [No Abstract]   [Full Text] [Related]  

  • 43. Focus on hepatitis. Weight-based versus fixed-dose peginterferons.
    Shaw-Stiffel T
    IAPAC Mon; 2004 May; 10(5):178-80. PubMed ID: 15366103
    [No Abstract]   [Full Text] [Related]  

  • 44. Peds-C.
    Hoofnagle JH
    Hepatology; 2005 Mar; 41(3):421. PubMed ID: 15723319
    [No Abstract]   [Full Text] [Related]  

  • 45. Antifibrotics for chronic hepatitis C.
    Pockros PJ
    Clin Liver Dis; 2009 Aug; 13(3):365-73. PubMed ID: 19628154
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Chronic hepatitis C. Better treatment outcome with pegylated interferon].
    MMW Fortschr Med; 2001 Mar; 143(13):51. PubMed ID: 11332022
    [No Abstract]   [Full Text] [Related]  

  • 47. [Indication of monotherapy with pegylated interferon or interferon for patient with HCV in Japan].
    Tamori A; Kawada N
    Nihon Rinsho; 2011 May; 69 Suppl 4():185-9. PubMed ID: 22096916
    [No Abstract]   [Full Text] [Related]  

  • 48. Cognitive function does not worsen during long-term low-dose peginterferon therapy in patients with chronic hepatitis C.
    Fontana RJ; Bieliauskas LA; Back-Madruga C; Lindsay KL; Litman HJ; Lok AS; Kronfol Z;
    Am J Gastroenterol; 2010 Jul; 105(7):1551-60. PubMed ID: 20104219
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Visual side effects of pegylated interferon during therapy for chronic hepatitis C infection.
    Willson RA
    J Clin Gastroenterol; 2004 Sep; 38(8):717-22. PubMed ID: 15319658
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Regression of hepatic fibrosis and cirrhosis in patients with chronic hepatitis C treated with interferon-based therapy.
    Metwally MA; Zein CO; Zein NN
    Gastroenterology; 2003 May; 124(5):1561. PubMed ID: 12760398
    [No Abstract]   [Full Text] [Related]  

  • 51. Nanomedicines in the treatment of chronic hepatitis C--focus on pegylated interferon alpha-2a.
    Thomas T; Foster G
    Int J Nanomedicine; 2007; 2(1):19-24. PubMed ID: 17722508
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of pegylated interferons for the treatment of chronic hepatitis C.
    Kozlowski A; Charles SA; Harris JM
    BioDrugs; 2001; 15(7):419-29. PubMed ID: 11520253
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Peginterferon is here to stay.
    Karnam US; Jaca I; Reddy KR
    Am J Gastroenterol; 2001 May; 96(5):1637-8. PubMed ID: 11374715
    [No Abstract]   [Full Text] [Related]  

  • 54. Splenectomy for thrombocytopenia in patients with hepatitis C cirrhosis.
    Davern TJ
    J Clin Gastroenterol; 2008 Aug; 42(7):863-4. PubMed ID: 18469723
    [No Abstract]   [Full Text] [Related]  

  • 55. Phase III hepatitis C program begins.
    AIDS Read; 2001 Feb; 11(2):85. PubMed ID: 11279886
    [No Abstract]   [Full Text] [Related]  

  • 56. Hepatitis C in the elderly: epidemiology, natural history, and treatment.
    Mindikoglu AL; Miller RR
    Clin Gastroenterol Hepatol; 2009 Feb; 7(2):128-34; quiz 124. PubMed ID: 19084480
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PEG-interferon versus conventional interferon and liver fibrosis: do we have evidence of superiority?
    Sander G; Picon PD; Fuchs FD; Beltrame A; De Souza RR
    Gastroenterology; 2003 Feb; 124(2):584; author reply 584-5. PubMed ID: 12557174
    [No Abstract]   [Full Text] [Related]  

  • 58. Letter: the efficacy of interferon-free regimens in HCV-related Child C cirrhosis needs careful interpretation-Authors' reply.
    Andriulli A; Guarino M; Morisco F
    Aliment Pharmacol Ther; 2017 Jul; 46(1):77. PubMed ID: 28589587
    [No Abstract]   [Full Text] [Related]  

  • 59. Hepatology. Interferon in chronic hepatitis C.
    Sánchez-Tapias JM; Rodés J
    Lancet; 1995 Dec 23-30; 346 Suppl():s11. PubMed ID: 9454028
    [No Abstract]   [Full Text] [Related]  

  • 60. Editorial: pegylated interferon combined with bulevirtide for chronic hepatitis delta-new life for an old timer?
    Riveiro-Barciela M; Palom A; Buti M
    Aliment Pharmacol Ther; 2022 Sep; 56(5):912-913. PubMed ID: 35934854
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.